Immix Biopharma, Inc. (NASDAQ:IMMX) Given Consensus Rating of "Moderate Buy" by Brokerages

Key Points

• Analyst sentiment is moderately bullish: Nine analysts rate Immix Biopharma a consensus “Moderate Buy,” with eight buys and one sell. The average 12-month price target is $21.29, implying potential upside from the $13.94 share price.
• Recent ratings include several favorable updates: HC Wainwright raised its target to $25, while Bank of America initiated coverage with a $27 target and a buy rating. Weiss Ratings maintained a sell rating, highlighting some disagreement among analysts.
• The company remains loss-making and clinical-stage: Immix Biopharma reported quarterly EPS of negative $0.18, slightly below estimates, and analysts expect a full-year loss of $0.74 per share. Its lead candidate, IMX-110, is being developed as an immuno-oncology therapy targeting the tumor microenvironment.

Immix Biopharma, Inc. (NASDAQ:IMMX - Get Free Report) has earned a consensus rating of "Moderate Buy" from the nine analysts that are covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating and eight have given a buy rating to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $21.2857.

Several research analysts have recently commented on IMMX shares. Lifesci Capital started coverage on Immix Biopharma in a research note on Wednesday, June 17th. They set an "outperform" rating and a $19.00 target price for the company. Citigroup restated a "market outperform" rating on shares of Immix Biopharma in a research note on Friday, August 14th. HC Wainwright raised their price objective on shares of Immix Biopharma from $20.00 to $25.00 and gave the stock a "buy" rating in a research report on Monday, August 10th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Immix Biopharma in a research note on Friday, July 17th. Finally, Bank of America initiated coverage on Immix Biopharma in a research report on Thursday, June 18th. They set a "buy" rating and a $27.00 price objective on the stock.

Immix Biopharma Stock Performance

NASDAQ IMMX opened at $13.94 on Monday. Immix Biopharma has a 12 month low of $1.94 and a 12 month high of $15.10. The stock has a 50 day moving average of $10.62 and a 200-day moving average of $9.56. The company has a market cap of $997.25 million, a PE ratio of -15.84 and a beta of 0.11.

Immix Biopharma (NASDAQ:IMMX - Get Free Report) last announced its quarterly earnings results on Friday, August 7th. The company reported ($0.18) EPS for the quarter, missing analysts' consensus estimates of ($0.17) by ($0.01). As a group, sell-side analysts predict that Immix Biopharma will post -0.74 EPS for the current fiscal year.

Institutional Investors Weigh In On Immix Biopharma

Institutional investors and hedge funds have recently bought and sold shares of the company. Allworth Financial LP bought a new stake in shares of Immix Biopharma during the 4th quarter worth $30,000. Legal & General Group Plc acquired a new position in shares of Immix Biopharma during the second quarter worth $41,000. Mathes Company Inc. bought a new stake in Immix Biopharma during the 4th quarter worth $56,000. Compass Financial Management LLC bought a new position in Immix Biopharma in the second quarter valued at about $56,000. Finally, Balyasny Asset Management L.P. acquired a new position in shares of Immix Biopharma in the fourth quarter valued at approximately $67,000. Institutional investors own 11.26% of the company's stock.

About Immix Biopharma

Immix Biopharma NASDAQ: IMMX is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company's approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company's lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source